Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Name: Kaimen Rigor review — IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Item: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Rating: 96
Author: Alpha1

Chertow GM, Chang AM, Felker GM, Heise M, Velkoska E, Fellström B, Charytan DM, Clementi R, Gibson CM, Goodman SG, Jardine M, Levin A, Lokhnygina Y, Mears J, Mehran R, Stenvinkel P, Wang AY, Wheeler DC, Zoccali C, Ridker PM, Mahaffey KW, Tricoci P, Wolf M

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03043-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3e861750-bab4-4392-bbfb-fe1070f86311" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3e861750-bab4-4392-bbfb-fe1070f86311/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e46c224eab01bca79308a2990b9ee67058233e07b573e7b22cabde4c2d030403

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Paper source

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is hs-CRP, a surrogate inflammatory biomarker, not a hard clinical outcome. The paper does not demonstrate target engagement at the tested doses (no PK/PD data) and does not cite validated evidence linking hs-CRP reduction to clinical outcomes in this population, though it references CANTOS as indirect support.
“The primary endpoint was the change from baseline in hs-CRP to week 12, expressed as the geometric mean ratio.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The effect size is reported as percentage reductions in hs-CRP (86-92%) relative to placebo, but no anchor to clinical meaningfulness is provided. The paper does not establish a minimal clinically important difference for hs-CRP or link the magnitude to improved clinical outcomes.
“Clazakizumab treatment significantly reduced serum hs-CRP concentrations at week 12 by 86%, 90% and 92% relative to placebo”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2b randomized controlled trial with strong methodology, clear ethics approvals, and transparent reporting. The main weakness is the vague data availability statement, which lacks a concrete access mechanism or timeframe. Minor reporting inconsistencies (P < 0.001 vs P < 0.0001) and a typo in the abstract should be corrected.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence in study type (interventional). The statistics verification component could not recompute any tests because only threshold p-values were reported; this does not confirm statistical correctness. The citation check found no retracted or unresolved references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Data look implausibly cleanAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites extensive prior work (CANTOS, lipid-lowering trials, Mendelian randomization) and acknowledges limitations of prior research (e.g., exclusion of ESKD patients from trials). The rationale linking IL-6 to cardiovascular risk in dialysis patients is clearly articulated, and the hypothesis follows logically. Limitations of prior research are addressed by designing a trial specifically in this population.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on IL-6 pathway, inflammation in ESKD, and prior trials, and provides a logical rationale for the study hypothesis.

Evidence

“Evidence suggests a causal role of activation of the interleukin-6 (IL-6) pathway”

Main, paragraph 1-2Find in source

“As such, it is plausible that a therapeutic approach targeting the IL-6 pathway could reduce cardiovascular events and mortality in patients receiving maintenance dialysis.”

Main, paragraph 2Find in source

“Patients with ESKD have been excluded from most cardiovascular outcome trials”

Main, paragraph 1Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior research on IL-6 pathway, inflammation, and cardiovascular risk in dialysis patients, and provides a logical rationale for the study.

Evidence

“Evidence suggests a causal role of activation of the interleukin-6 (IL-6) pathway”

Introduction ¶1Find in source

“As such, it is plausible that a therapeutic approach targeting the IL-6 pathway could reduce cardiovascular events and mortality in patients receiving maintenance dialysis.”

Introduction ¶4Find in source

“Patients with ESKD have been excluded from most cardiovascular outcome trials”

Introduction ¶1Find in source

Randomization method is described (1:1:1:1 ratio, stratified by hs-CRP), blinding is stated (all participants and investigators blinded), and a power analysis is provided (30 per group, >97% power). Inclusion/exclusion criteria are detailed. Outlier handling is addressed through pre-specified analysis sets (PP, mITT, safety). Controls are the placebo group. Independent replication is not applicable for a single pivotal trial, but the primary analysis was independently verified by Stanford Quantitative Sciences Center.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with adequate sample size calculation and pre-specified analysis populations.

Evidence

“Eligible patients were randomly allocated in a 1:1:1:1 ratio to placebo or clazakizumab at doses of 2.5 mg, 5 mg or 10 mg. Randomization was stratified by hs-CRP 2–6 mg l −1 or >6 mg l −1 at screening”

MethodsFind in source

“All participants and investigators were blinded to treatment assignment.”

MethodsFind in source

“we determined that a sample size of 30 participants per group (120 in total) would provide >97% power to detect an 80% reduction (GMR to placebo of 0.2, equal to −1.61 on the log scale) in hs-CRP”

MethodsFind in source

PASSReviewer 2· 95% conf

The study design is rigorous: randomized, double-blind, placebo-controlled, with adequate sample size calculation and pre-specified analysis populations.

Evidence

MethodsFind in source

“All participants and investigators were blinded to treatment assignment.”

MethodsFind in source

Sex is reported for all groups (e.g., 65.6% male in 2.5 mg group). Age is reported as median and range. Demographics include race, ethnicity, BMI, and comorbidities. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, ethnicity, and comorbidities.

Evidence

“Male, n (%) | 21 (65.6) | 18 (56.3) | 25 (78.1) | 21 (67.7)”

Table 1Find in source

“Age (year), median (range) | 63 (39, 83) | 67 (36, 82) | 63 (31, 83) | 69 (36, 86)”

Table 1Find in source

“Race | White, n (%) | 21 (65.6) | 18 (56.3) | 17 (53.1) | 13 (41.9)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, ethnicity, and comorbidities.

Evidence

“Male, n (%) | 21 (65.6) | 18 (56.3) | 25 (78.1) | 21 (67.7)”

Table 1Find in source

“Age (year), median (range) | 63 (39, 83) | 67 (36, 82) | 63 (31, 83) | 69 (36, 86)”

Table 1Find in source

“Race | White, n (%) | 21 (65.6) | 18 (56.3) | 17 (53.1) | 13 (41.9)”

Table 1Find in source

The paper states that Ethics Committees and Institutional Review Boards affiliated with each site approved the protocol, and all participants provided written informed consent. This satisfies both irb_ethics_statement and informed_consent. Regulatory compliance is implied by adherence to Good Clinical Practice (not explicitly named but the trial is registered and conducted under standard regulations).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are clearly documented, with named ethics committees and written informed consent.

Evidence

“Ethics Committees and Institutional Review Boards affiliated with each site approved the protocol.”

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported: named ethics committees approved the protocol, and written informed consent was obtained.

Evidence

“Ethics Committees and Institutional Review Boards affiliated with each site approved the protocol.”

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

Clazakizumab is identified as a humanized monoclonal antibody targeting IL-6, with doses specified. The manufacturer (CSL Behring) is implied through funding and author affiliations. Statistical software (SAS 9.4) is identified. Other bench resources (antibodies, cell lines, etc.) are not applicable as this is a clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (clazakizumab) is identified with manufacturer and dose, and statistical software is identified.

Evidence

“Clazakizumab is a high-affinity humanized monoclonal antibody that targets the IL-6 ligand”

Main, paragraph 2Find in source

“We conducted all analyses using SAS version 9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (clazakizumab) is adequately identified, and statistical software is named.

Evidence

“Clazakizumab is a high-affinity humanized monoclonal antibody that targets the IL-6 ligand”

Introduction ¶4Find in source

“We conducted all analyses using SAS version 9.4 (SAS Institute).”

Statistical analysisFind in source

The primary analysis uses MMRM with t-tests, and p-values are reported as <0.001 (exact values not given but acceptable for large effects). Effect sizes are reported as GMRs with 95% CIs. Software is identified. Data presentation includes individual data points (waterfall plots) and per-group n. Mathematical plausibility checks: baseline characteristics appear plausible; no obvious arithmetic errors detected.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported and effect sizes with confidence intervals.

Evidence

“T tests from the MMRM model were used to calculate P values.”

Statistical analysisFind in source

“Serum hs-CRP concentrations at week 12 decreased by 86%, 90% and 92% in patients randomized to 2.5 mg, 5 mg or 10 mg clazakizumab, respectively, and increased by 19% in patients randomized to placebo (all P < 0.001 compared with placebo; Fig. ).”

ResultsFind in source

“Figure shows the individual patient change in hs-CRP (waterfall plots) for all groups”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported and effect sizes with confidence intervals.

Evidence

“T tests from the MMRM model were used to calculate P values.”

Statistical analysisFind in source

“all P < 0.001 compared with placebo”

ResultsFind in source

“GMRs to baseline (95% CI) of serum hs-CRP concentrations”

Figure 2Find in source

The data availability statement says data are not currently available and will be made available by request to the sponsor at the end of the trial, pending review committee approval. This is reported_but_inadequate because it lacks a concrete platform or timeframe. No code sharing is mentioned, but no bespoke code is described.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement is present but vague, stating data will be available by request at the end of the ongoing trial without a concrete mechanism or timeframe.

Evidence

“The data that support the findings of this study are not currently available as the phase 3 study is ongoing. Individual participant data that underlie the results reported will be made available by request to the sponsor at the end of the ongoing trial, provided the proposed use of data has been approved by the review committee.”

Data availabilityFind in source

WARNReviewer 2· 90% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe.

Evidence

“Individual participant data that underlie the results reported will be made available by request to the sponsor at the end of the ongoing trial, provided the proposed use of data has been approved by the review committee.”

Data availabilityFind in source

Trial registration number is provided (NCT05485961). Methods are comprehensive. Limitations are explicitly discussed (modest sample size, short follow-up, potential for infections). Conclusions are appropriately cautious, noting the need for a phase 3 trial. Funding and competing interests are disclosed. Reporting guideline (CONSORT) is implied by the CONSORT diagram, though not explicitly referenced.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

“ClinicalTrials.gov registration: NCT05485961”

AbstractFind in source

“Limitations of the trial include a modest sample size and a relatively short duration of follow-up.”

DiscussionFind in source

“G.M.C. has served on the Board of Directors of Satellite Healthcare, a nonprofit dialysis provider. His institution (Stanford University) has received a grant from the trial sponsor, CSL Behring.”

Competing interestsFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent: methods are detailed, trial is registered, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov registration: NCT05485961”

AbstractFind in source

“Limitations of the trial include a modest sample size and a relatively short duration of follow-up.”

Discussion ¶5Find in source

Competing interestsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 39 references by DOI: 38 verified — 1 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and generally well-reported; an informed reader should weigh the vague data availability statement and the minor P-value inconsistency as minor limitations. No erratum is warranted for the P-value discrepancy, but the authors should consider issuing a correction for the typo and clarifying the data access plan.

1.
HIGHdata code
In the Data availability section, specify a concrete access mechanism (e.g., a data-sharing platform like Vivli or YODA) and a timeframe for when data will be available, moving from 'on request' to a managed-access statement.
The current statement is vague and lacks a concrete platform or timeframe, which is a common reviewer concern and limits reproducibility.
2.
HIGHreporting
In the Methods, explicitly name the reporting guideline followed (e.g., CONSORT) and state that the checklist is submitted, to strengthen transparency.
The CONSORT diagram is present but the guideline is not explicitly referenced, which is a minor reporting gap.
3.
MEDIUMcopyedit
In the Abstract, correct the typo 'signficantly' to 'significantly'.
Typographical error in the abstract should be fixed for professionalism.
4.
MEDIUMcopyedit
In the Results, Primary outcome, ensure consistent use of P < 0.001 vs P < 0.0001 between the abstract and results section.
The abstract states P < 0.0001 while the results state P < 0.001; this inconsistency should be resolved.
5.
MEDIUMstatistics
In the Methods, Statistical analysis, clarify that the t-tests from the MMRM model are two-sided.
The two-sided nature is mentioned elsewhere but not in this sentence, which could cause confusion.
6.
MEDIUMreporting
In the Methods, describe the blinding of outcome assessors and data analysts explicitly, as only participants and investigators are mentioned.
Clarifying who was blinded strengthens the description of blinding procedures.
7.
MEDIUMreporting
In the Methods, include a statement on whether the trial was conducted in accordance with ICH-GCP or the Declaration of Helsinki.
Explicitly naming the ethical standard enhances regulatory compliance reporting.
8.
MEDIUMreporting
In the Methods, clarify the role of the independent data monitoring committee and whether any interim analyses were pre-specified.
This information is important for assessing trial conduct and potential bias.
9.
MEDIUMdata code
In the Data availability section, clarify whether the data will be deposited in a public repository after the phase 3 trial, or if it will remain under managed access.
Clarifying the long-term data sharing plan improves transparency.
10.
LOWreporting
In the Discussion, consider adding a note on the generalizability of findings to peritoneal dialysis patients, as they were excluded from this phase.
Expanding on this limitation helps readers interpret the applicability of the results.
11.
LOWdata code
Consider sharing the statistical analysis code (e.g., SAS code) in a public repository to facilitate reproducibility.
Sharing code enhances reproducibility, though it is not strictly required.
12.
LOWreporting
Provide a CONSORT checklist as supplementary material to confirm adherence to reporting standards.
A checklist would strengthen the reporting transparency claim.

Full text (39,051 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03043-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/3e861750-bab4-4392-bbfb-fe1070f86311" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/3e861750-bab4-4392-bbfb-fe1070f86311/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e46c224eab01bca79308a2990b9ee67058233e07b573e7b22cabde4c2d030403

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is hs-CRP, a surrogate inflammatory biomarker, not a hard clinical outcome. The paper does not demonstrate target engagement at the tested doses (no PK/PD data) and does not cite validated evidence linking hs-CRP reduction to clinical outcomes in this population, though it references CANTOS as indirect support.
“The primary endpoint was the change from baseline in hs-CRP to week 12, expressed as the geometric mean ratio.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The effect size is reported as percentage reductions in hs-CRP (86-92%) relative to placebo, but no anchor to clinical meaningfulness is provided. The paper does not establish a minimal clinically important difference for hs-CRP or link the magnitude to improved clinical outcomes.
“Clazakizumab treatment significantly reduced serum hs-CRP concentrations at week 12 by 86%, 90% and 92% relative to placebo”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

Data look implausibly cleanAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on IL-6 pathway, inflammation in ESKD, and prior trials, and provides a logical rationale for the study hypothesis.

Evidence

“Evidence suggests a causal role of activation of the interleukin-6 (IL-6) pathway”

Main, paragraph 1-2Find in source

“As such, it is plausible that a therapeutic approach targeting the IL-6 pathway could reduce cardiovascular events and mortality in patients receiving maintenance dialysis.”

Main, paragraph 2Find in source

“Patients with ESKD have been excluded from most cardiovascular outcome trials”

Main, paragraph 1Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior research on IL-6 pathway, inflammation, and cardiovascular risk in dialysis patients, and provides a logical rationale for the study.

Evidence

“Evidence suggests a causal role of activation of the interleukin-6 (IL-6) pathway”

Introduction ¶1Find in source

“As such, it is plausible that a therapeutic approach targeting the IL-6 pathway could reduce cardiovascular events and mortality in patients receiving maintenance dialysis.”

Introduction ¶4Find in source

“Patients with ESKD have been excluded from most cardiovascular outcome trials”

Introduction ¶1Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with adequate sample size calculation and pre-specified analysis populations.

Evidence

MethodsFind in source

“All participants and investigators were blinded to treatment assignment.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study design is rigorous: randomized, double-blind, placebo-controlled, with adequate sample size calculation and pre-specified analysis populations.

Evidence

MethodsFind in source

“All participants and investigators were blinded to treatment assignment.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, race, ethnicity, and comorbidities.

Evidence

“Male, n (%) | 21 (65.6) | 18 (56.3) | 25 (78.1) | 21 (67.7)”

Table 1Find in source

“Age (year), median (range) | 63 (39, 83) | 67 (36, 82) | 63 (31, 83) | 69 (36, 86)”

Table 1Find in source

“Race | White, n (%) | 21 (65.6) | 18 (56.3) | 17 (53.1) | 13 (41.9)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, ethnicity, and comorbidities.

Evidence

“Male, n (%) | 21 (65.6) | 18 (56.3) | 25 (78.1) | 21 (67.7)”

Table 1Find in source

“Age (year), median (range) | 63 (39, 83) | 67 (36, 82) | 63 (31, 83) | 69 (36, 86)”

Table 1Find in source

“Race | White, n (%) | 21 (65.6) | 18 (56.3) | 17 (53.1) | 13 (41.9)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are clearly documented, with named ethics committees and written informed consent.

Evidence

“Ethics Committees and Institutional Review Boards affiliated with each site approved the protocol.”

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported: named ethics committees approved the protocol, and written informed consent was obtained.

Evidence

“Ethics Committees and Institutional Review Boards affiliated with each site approved the protocol.”

MethodsFind in source

“All participants provided written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (clazakizumab) is identified with manufacturer and dose, and statistical software is identified.

Evidence

“Clazakizumab is a high-affinity humanized monoclonal antibody that targets the IL-6 ligand”

Main, paragraph 2Find in source

“We conducted all analyses using SAS version 9.4 (SAS Institute).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (clazakizumab) is adequately identified, and statistical software is named.

Evidence

“Clazakizumab is a high-affinity humanized monoclonal antibody that targets the IL-6 ligand”

Introduction ¶4Find in source

“We conducted all analyses using SAS version 9.4 (SAS Institute).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported and effect sizes with confidence intervals.

Evidence

“T tests from the MMRM model were used to calculate P values.”

Statistical analysisFind in source

ResultsFind in source

“Figure shows the individual patient change in hs-CRP (waterfall plots) for all groups”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported and effect sizes with confidence intervals.

Evidence

“T tests from the MMRM model were used to calculate P values.”

Statistical analysisFind in source

“all P < 0.001 compared with placebo”

ResultsFind in source

“GMRs to baseline (95% CI) of serum hs-CRP concentrations”

Figure 2Find in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement is present but vague, stating data will be available by request at the end of the ongoing trial without a concrete mechanism or timeframe.

Evidence

Data availabilityFind in source

WARNReviewer 2· 90% conf

A data availability statement is present but vague, lacking a concrete access mechanism or timeframe.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

“ClinicalTrials.gov registration: NCT05485961”

AbstractFind in source

“Limitations of the trial include a modest sample size and a relatively short duration of follow-up.”

DiscussionFind in source

Competing interestsFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent: methods are detailed, trial is registered, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov registration: NCT05485961”

AbstractFind in source

“Limitations of the trial include a modest sample size and a relatively short duration of follow-up.”

Discussion ¶5Find in source

Competing interestsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 39 references by DOI: 38 verified — 1 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data availability section, specify a concrete access mechanism (e.g., a data-sharing platform like Vivli or YODA) and a timeframe for when data will be available, moving from 'on request' to a managed-access statement.
The current statement is vague and lacks a concrete platform or timeframe, which is a common reviewer concern and limits reproducibility.
2.
HIGHreporting
In the Methods, explicitly name the reporting guideline followed (e.g., CONSORT) and state that the checklist is submitted, to strengthen transparency.
The CONSORT diagram is present but the guideline is not explicitly referenced, which is a minor reporting gap.
3.
MEDIUMcopyedit
In the Abstract, correct the typo 'signficantly' to 'significantly'.
Typographical error in the abstract should be fixed for professionalism.
4.
MEDIUMcopyedit
In the Results, Primary outcome, ensure consistent use of P < 0.001 vs P < 0.0001 between the abstract and results section.
The abstract states P < 0.0001 while the results state P < 0.001; this inconsistency should be resolved.
5.
MEDIUMstatistics
In the Methods, Statistical analysis, clarify that the t-tests from the MMRM model are two-sided.
The two-sided nature is mentioned elsewhere but not in this sentence, which could cause confusion.
6.
MEDIUMreporting
In the Methods, describe the blinding of outcome assessors and data analysts explicitly, as only participants and investigators are mentioned.
Clarifying who was blinded strengthens the description of blinding procedures.
7.
MEDIUMreporting
In the Methods, include a statement on whether the trial was conducted in accordance with ICH-GCP or the Declaration of Helsinki.
Explicitly naming the ethical standard enhances regulatory compliance reporting.
8.
MEDIUMreporting
In the Methods, clarify the role of the independent data monitoring committee and whether any interim analyses were pre-specified.
This information is important for assessing trial conduct and potential bias.
9.
MEDIUMdata code
In the Data availability section, clarify whether the data will be deposited in a public repository after the phase 3 trial, or if it will remain under managed access.
Clarifying the long-term data sharing plan improves transparency.
10.
LOWreporting
In the Discussion, consider adding a note on the generalizability of findings to peritoneal dialysis patients, as they were excluded from this phase.
Expanding on this limitation helps readers interpret the applicability of the results.
11.
LOWdata code
Consider sharing the statistical analysis code (e.g., SAS code) in a public repository to facilitate reproducibility.
Sharing code enhances reproducibility, though it is not strictly required.
12.
LOWreporting
Provide a CONSORT checklist as supplementary material to confirm adherence to reporting standards.
A checklist would strengthen the reporting transparency claim.

Full text (39,051 chars)Analyzed: Aug 16, 2026